- Meeting abstract
- Open Access
C-type natriuretic peptide chronic administration attenuates cardiac fibrosis and inflammation in spontaneously hypertensive rats
BMC Pharmacology and Toxicology volume 16, Article number: A104 (2015)
Growing evidence shows that the expression and release of a number of inflammatory cytokines are increased in hypertension [1, 2] and are also present at sites of cardiovascular fibrosis. In fact, many of these inflammatory mediators are responsible for the activation of collagen producing fibroblasts . In addition, proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) have shown to stimulate the release of C-type natriuretic peptide (CNP), indicating a potential role of CNP as a modulator of the inflammatory process . The aim of the present study was to evaluate the effects of chronic CNP treatment on cardiac fibrosis and inflammation in spontaneously hypertensive rats (SHR).
Experimental design and methods
12-week-old male SHR and Wistar rats were infused through osmotic pumps with CNP (0,75 µg/hr) or saline (S) for 14 days. Systolic blood pressure (SBP, mmHg) was recorded by tail-cuff method. At the end of the treatment, the left ventricle (LV) was extracted to determine left ventricular mass index (LVMI, g LV/mm tibia length), the myocyte area (µm2, Haematoxylin and Eosin-stain), fibrosis (% collagen, Picrosirius Red stain) and inflammation parameters (IL-6 and TNF-α, % stain/mm2 by immunohistochemistry, IHC and IL-6, TNF-α and IL-1β, pg/mg protein by ELISA).
Characteristic high SBP values in SHR are accompanied by hypertrophy, fibrosis and a higher presence of inflammatory cytokines.
Our results show that chronic treatment with CNP attenuates the expression of proinflammatory markers and the early signs of fibrosis in cardiac tissue of hypertensive rats. These effects, combined with the drop in blood pressure we observed, indicate that CNP could possibly have an important pathophysiological and therapeutical role in preventing or even reversing cardiac fibrosis and inflammation accompanying left ventricular remodelling in arterial hypertension.
Sanz-Rosa D, Oubiña MP, Cediel E, de Las Heras N, Vegazo O, Jiménez J, Lahera V, Cachofeiro V: Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol. 2005, 288: H111-H115.
Dinh QN, Drummond GR, Sobey CG, Chrissobolis S: Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014, 2014: 406960-
Lee SB, Kalluri R: Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl. 2010, 119: S22-S26.
Osterbur K1, Yu DH, DeClue AE: Interleukin-1β, tumour necrosis factor-α and lipopolysaccharide induce C-type natriuretic peptide from canine aortic endothelial cells. Res Vet Sci. 2013, 94: 478-83. 10.1016/j.rvsc.2012.10.002.
About this article
Cite this article
Prentki, E.S., Caniffi, C., Bouchet, G. et al. C-type natriuretic peptide chronic administration attenuates cardiac fibrosis and inflammation in spontaneously hypertensive rats. BMC Pharmacol Toxicol 16, A104 (2015). https://0-doi-org.brum.beds.ac.uk/10.1186/2050-6511-16-S1-A104
- Inflammatory Cytokine
- Left Ventricular Mass
- Ventricular Remodelling
- Left Ventricular Mass Index
- Left Ventricular Remodelling